373110
Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. Xcell Therapeutics Inc. was incorporated in 2015 and is based in Seoul, South Korea.
Market Cap & Net Worth: 373110 (373110)
373110 (KQ:373110) has a market capitalization of $12.74 Million (₩18.66 Billion) as of March 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #29891 globally and #2006 in its home market, demonstrating a 11.18% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 373110's stock price ₩1502.00 by its total outstanding shares 12421961 (12.42 Million).
373110 Market Cap History: 2024 to 2026
373110's market capitalization history from 2024 to 2026. Data shows change from $34.49 Million to $12.74 Million (-64.12% CAGR).
373110 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 373110's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
373110's market cap is 0.02 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $34.49 Million | $1.93 Billion | -$9.54 Billion | 0.02x | N/A |
Competitor Companies of 373110 by Market Capitalization
Companies near 373110 in the global market cap rankings as of March 19, 2026.
Key companies related to 373110 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
373110 Historical Marketcap From 2024 to 2026
Between 2024 and today, 373110's market cap moved from $34.49 Million to $ 12.74 Million, with a yearly change of -64.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩12.74 Million | -9.57% |
| 2025 | ₩14.09 Million | -59.14% |
| 2024 | ₩34.49 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of 373110 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.74 Million USD |
| MoneyControl | $12.74 Million USD |
| MarketWatch | $12.74 Million USD |
| marketcap.company | $12.74 Million USD |
| Reuters | $12.74 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.